---
schema_version: "secwatch.filing_event.v1"
accession: "0001388658-24-000096"
form_type: "8-K"
ticker: "IRTC"
cik: "0001388658"
company_name: "iRhythm Holdings, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:14:23.542481+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# iRhythm Q1 revenue $131.9M (+18.4% YoY); net loss widens to $45.7M; raises FY revenue guidance to $578-588M

## Summary
- Revenue $131.9M (+18.4% YoY); gross margin 66.3% (down 160 bps YoY).
- Net loss $45.7M ($1.47/share) vs $39.1M ($1.29) YoY; adjusted loss $38.1M ($1.23) vs $33.4M ($1.10).
- FY2024 revenue guidance raised to $578-588M (17-19% growth); gross margin 68-69%, adj. EBITDA margin 3-4%.
- Over 500K registrations in Q1; announced Epic Aura collaboration for EMR integration; heart failure prediction data presented at ACC.
- Unrestricted cash, equivalents, and marketable securities $569.1M as of March 31, 2024.

## SEC filing metadata
- accession: 0001388658-24-000096
- form_type: 8-K
- ticker: IRTC
- cik: 0001388658
- company_name: iRhythm Holdings, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388658/000138865824000096/0001388658-24-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388658/000138865824000096/irtc-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001388658-24-000096
- JSON: https://secwatch.observer/filing/0001388658-24-000096.json
- Plain text: https://secwatch.observer/filing/0001388658-24-000096.txt

## Key facts
- Earnings Releases
  iRhythm Holdings, Inc. reported three months ended March 31, 2024 results: revenue $131.9 million, net income $45.7 million, or a diluted loss of $1.47 per share, EPS $1.47 per share. Guidance raised.
  - Period: three months ended March 31, 2024
  - Revenue: $131.9 million
  - Net income: $45.7 million, or a diluted loss of $1.47 per share
  - EPS: $1.47 per share
  - Guidance: raised
  - Result: reported results
  source text: that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights • Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023 • Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023 • Unrestricted cash, cash equivalents and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1388658/000138865824000096/0001388658-24-000096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.